Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Sarah Boyce currently holds 19,000 shares of LIGAND PHARMACEUTICALS INC (LGND), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Sarah Boyce has been a net seller of LGND stock. They have purchased $101.3K and sold $30.0M worth of shares.
Sarah Boyce's most recent insider trade was on Jun 26, 2026, when they sold 19,000 shares at $0.00 per share.
Sarah Boyce serves as Executive at LIGAND PHARMACEUTICALS INC (LGND). They have executed 100 insider transactions totaling $30.1M over their tenure at the company.
Sarah Boyce holds the position of Executive at LIGAND PHARMACEUTICALS INC, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 11 years and currently hold a stake valued at $0.
Sarah Boyce has shown a selling trading pattern, with $101.3K in total purchases and $30.0M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Sarah Boyce was on Jun 13, 2024, when they sold $6.6M worth of RNA shares. This transaction involved 164,233 shares at $40.08 per share.
Sarah Boyce currently owns 19,000 shares of LIGAND PHARMACEUTICALS INC (LGND), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Sarah Boyce's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Sarah Boyce has 100 Form 4 filings on record as an insider at LIGAND PHARMACEUTICALS INC.
Set alerts for Sarah Boyce and 40,000+ other insiders.